UNSPSC 51385617: Aspirin methyl ester

This classification denotes a cyclooxygenase inhibitor with the molecular formula C10H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FX481V180, chemically known as benzoic acid, 2-(acetyloxy)-, methyl ester, but more generally known as aspirin methyl ester, which bears US NIH Compound Identifier 68484. European Medicines Agency schedules aspirin methyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435.

Most nations, for tariff purposes, schedule aspirin methyl ester under HS 29182200. SMILES: CC(=O)OC1CCCCC1C(=O)OC.

UNSPSC 51385617 Aspirin methyl ester is a Commodity code that in recent state and local procurement activity does not align with the product it nominally describes. The three most recent opportunities posted under this code solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are aspirin methyl ester. The code shows little relevant recent activity for its stated product, and the opportunities present appear to reflect tagging misalignment rather than actual procurement of aspirin methyl ester by state and local buyers.

Issuing bodies soliciting under or near this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023, per the opportunity record) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, including Oregon. Activity appears concentrated in the South and Midwest, though the code's nominal scope and actual recent solicitations diverge substantially enough to warrant verification before pursuing opportunities tagged to this code.